Patent estate

Hisamitsu Pharmaceutical Co., Inc. — Patent Portfolio

1 drug with active patents · 14 active patents · 0 expired · 0 biologics with BPCIA exclusivity

AI-enriched 14/14 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

§
Strategic Patent Estate Brief
AI-grounded executive summary · generated 2026-05-16

Verdict Hisamitsu Pharmaceutical Co., Inc.'s portfolio is relatively weak with a high average vulnerability score, and the company faces a significant cliff year in 2030 with 1 drug losing exclusivity.

Portfolio overview Hisamitsu Pharmaceutical Co., Inc. has a total of 6 drugs in its portfolio, with 1 of them having patents. The company has a total of 14 US patents, all of which are active. The average vulnerability score of the company's patents is 57, indicating a relatively high level of vulnerability. The company has no ironclad patents and no vulnerable patents.

Cliff calendar The company faces a significant cliff year in 2030, with 1 drug losing exclusivity. Specifically, Voltaren will lose exclusivity in 2030. Additionally, the company will see 1 drug lose exclusivity in 2030.

Most exposed drugs The top drug facing near-term loss of exclusivity is Voltaren, with an earliest active patent expiry date of 2030-04-23 and an average vulnerability score of 57. Unfortunately, the annual revenue for Voltaren is not available.

Biologic exclusivity Hisamitsu Pharmaceutical Co., Inc. has no biologics in its portfolio.

Strategic implications The company faces a total of $0 in revenue at risk in the next 5 years. Given the company's portfolio, it may consider lifecycle moves such as subQ switches, label extensions, or combination filings to maintain revenue and competitiveness.

Sources: FDA Orange Book · FDA Purple Book · INPADOC family · USPTO · vulnerability scoring. Not legal advice.

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2030

Patent estate by drug

Voltaren (DICLOFENAC)

Cliff 2030 · 4y
Method of Use 6 Formulation 8
  • US9186328 Vuln 68 2030-04-23
    This patent protects methods for producing particles of diclofenac and using them in medicaments for treating animals, including humans.
  • US9180095 Vuln 68 2030-04-23
    This patent protects methods for producing particles of diclofenac and using them in medicaments for treating animals, including humans.
  • US9186328 Vuln 68 2030-04-23
    This patent protects methods for producing particles of diclofenac and using them in medicaments for treating animals, including humans.
See all 14 patents →

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Formulation 8 patents
  • Method of Use 6 patents

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track Hisamitsu Pharmaceutical Co., Inc.'s patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export